Atebimetinib (IMM-1-104) + Modified Gemcitabine/Nab-Paclitaxel (mGnP) Shows Extraordinary Overall Survival (OS) and Favorable Tolerability in First-Line (1L) Metastatic PDAC: Updated Phase 2 Results

Presented as an Encore Presentation at the PanCAN Scientific Summit on September 28th, 2025.